Health & Fitness
Health and Fitness
Health and Fitness 
Thu, January 29, 2009
[ Thu, Jan 29th 2009
] - Market Wire
[ Thu, Jan 29th 2009
] - Market Wire
[ Thu, Jan 29th 2009
] - Market Wire
[ Thu, Jan 29th 2009
] - Market Wire
[ Thu, Jan 29th 2009
] - Market Wire
[ Thu, Jan 29th 2009
] - Market Wire
[ Thu, Jan 29th 2009
] - Market Wire
Wed, January 28, 2009
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
[ Wed, Jan 28th 2009
] - Market Wire
Resumen: Gilead esboza las prioridades de I+D para 2009
FOSTER CITY, California--([ BUSINESS WIRE ])--Gilead Sciences, Inc. (Nasdaq:GILD) ha subrayado las prioridades de desarrollo clínico de la empresa para 2009 como parte de su rueda de prensa de resultados del cuarto trimestre y de ejercicio 2008 completo. Entre las más significantes actualizaciones está la notificación de que la Agencia de Alimentos y Fármacos de EE.UU. (FDA en sus siglas en inglés) ha aprobado los programas de desarrollo de elvitegravir, GS 9350 y un régimen de combinación de dosis fija de elvitegravir, GS 9350 y Truvada® (emtricitabina y fumarato de tenofovir disoproxil), la discusión de la cronología de los anuncios clínicos de darusentan en 2009 y un mayor énfasis en esforzarse por progresar en el desarrollo de compuestos para tratar el virus de la infección de la hepatitis C (HCV en sus siglas en inglés) y enfermedad hepática.
El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La traducción es solamente un medio de ayuda y deberá ser comparada con el texto en idioma original, que es la única versión del texto que tendrá validez legal.
Similar Health and Fitness Articles
[ Tue, Jan 27th 2009
] - Market Wire
[ Mon, Jan 12th 2009
] - Market Wire
[ Tue, Dec 23rd 2008
] - Market Wire
[ Tue, Dec 23rd 2008
] - Market Wire
[ Mon, Dec 22nd 2008
] - Market Wire
[ Fri, Dec 19th 2008
] - Market Wire
[ Thu, Dec 18th 2008
] - Market Wire
[ Fri, Dec 05th 2008
] - Market Wire
[ Wed, Nov 19th 2008
] - Market Wire
[ Mon, Nov 17th 2008
] - Market Wire